2 chapters across the catalog
A retrospective on the Fen-Phen litigation reveals that lawyers pocketed the majority of a $200 million settlement, leaving victims with less than a quarter of the funds. The hosts investigate whether Ozempic is classified as a "biologic," which would grant it certain legal protections. They conclude that because it is not a biologic, it remains vulnerable to the same type of mass tort litigation that ended Fen-Phen.
The hosts compare the ADOS claim for reparations to a shareholder class action lawsuit against a corporation like Monsanto. They argue that being ADOS is equivalent to holding a share of stock in the United States between 1619 and 1968, entitling the holder to a settlement regardless of how they spend the money. This framework is intended to separate those with a specific lineage of American slavery from other Black immigrants, potentially ending a "victimization mentality" through paperwork and verification.
